EHG Reviewing the Global Fund Market Shaping Strategy

As part of its evaluation of the 2012-2016 Strategy, the Global Fund commissioned EHG to conduct a Thematic Review on Market Shaping to examine the Global Fund’s role in shaping the market for key pharmaceuticals and diagnostic from 2011 through 2014. The purpose of the review is to inform further discussions within the Global Fund Secretariat and Board on the Global Fund role and progress in shaping the market for HIV, TB, and Malaria products. The findings of the review will inform the revision of the current Market Shaping Strategy and the development of the Global Fund Strategy 2017-2021.

In addition to reviewing implementation processes and market outcomes (price, volume, number of suppliers), the review team will develop strategic recommendations geared towards improvements in the Global Fund’s overall market shaping activities, including monitoring and evaluation of results.

The review is guided by three core questions:

  1. To what extent has the Global Fund leveraged its purchasing power to ensure that implementers procure the most cost-effective, WHO-recommended health products or regimens that meet the Global Fund quality assurance policies? 
  2. To what extent has the Global Fund accelerated the introduction and maturation of new, more cost-effective products for the prevention, diagnosis, and treatment of the three diseases?
  3. To what extent has the Global Fund ensured the continued availability, affordability, and innovation of products, including those for which there are not currently sustainable market conditions?

The review team will also attempt to gauge some measurable impacts to date of the Global Fund market shaping strategy and interventions. Further, it aims to quantify the savings achieved through enhanced procurement operations, and assess how these savings may have been used to benefit Global Fund or country programmes’ ability to reach more people.